UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

Dynavax Technologies Corporation

(Name of Issuer)

Common Stock, \$0.001 par value

(Title of Class of Securities)

268158201

(CUSIP Number)

May 11, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

⊠ Rule 13d-1(c)

o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 268158201	SCHEDULE 13G	Page 2 of 9 Pages
---------------------	--------------	-------------------

	1				
1	NAME OF REPORTING PERSONS				
	Deep Track Capita	Deep Track Capital, LP			
	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				
2	(a) o (b) x				
	SEC USE ONLY				
3					
CITIZENSHIP OR PLACE OF ORGANIZATION		OF ORGANIZATION			
4					
	Delaware		SOLE VOTING POWER		
		5	SOLE VOTING POWER		
NU	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		0		
S			SHARED VOTING POWER		
			6,556,180		
			SOLE DISPOSITIVE POWER		
			0		
			SHARED DISPOSITIVE POWER		
		8	6,556,180		
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9	6,556,180				
	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0				
10	U TILL AGGREGATE ATTION (J) EACLODES CERTAIN STANES				
	DED CENTE OF CLASS DEPRESENTED BY AMOUNT IN DOW (0)				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	5.10%				
12	TYPE OF REPORTING PERSON				
12	IA, OO				

_	II.			1	
4	NAME OF REPORTING PERSONS				
1	Deen Track Biotec	Doop Track Piotochnology Mactor Fund, Ltd			
	-	Deep Track Biotechnology Master Fund, Ltd.			
2	(a) o	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
_	(b) x				
	SEC USE ONLY				
3					
4	CITIZENSHIP OR PLACE OF ORGANIZATION				
4	Cayman Islands				
	<u> </u>		SOLE VOTING POWER		
		5			
NI	JMBER OF		0		
5	SHARES	6	SHARED VOTING POWER		
	BENEFICIALLY OWNED BY EACH REPORTING		6,556,180		
			SOLE DISPOSITIVE POWER		
RE			SOLE DISPOSITIVE FOWER		
PERSON WITH		7	0		
	WIIH		SHARED DISPOSITIVE POWER		
8 6,556,180		8	6 556 190		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	6,556,180				
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0				
	DED CENT OF C	DED CENTE OF CV ACC DEPDECENTED BY AN OVINT BY DOLL (6)			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	5.10%				
	TYPE OF REPORTING PERSON				
12	CO				
	CO				

	_				
1	NAME OF REPORTING PERSONS				
1	David Kroin	David Kroin			
		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
2	(a) o				
	(b) x				
	SEC USE ONLY				
3					
CITIZENSHIP OR PLACE OF ORGANIZATION		R PLACE	OF ORGANIZATION		
4					
	United States		1		
		5	SOLE VOTING POWER		
			0		
	JMBER OF SHARES	6	SHARED VOTING POWER		
BEN	BENEFICIALLY OWNED BY EACH REPORTING		0.750.400		
O			6,556,180		
RE			SOLE DISPOSITIVE POWER		
PERSON		7	0		
	WITH		SHARED DISPOSITIVE POWER		
		8	6,556,180		
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9					
	6,556,180				
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0				
10					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11	5.10%				
	TYPE OF REPORTING PERSON				
12					
	IN, HC				

CUSII	P No. 268158201	SCHEDULE 13G	Page 5 of 9 Pages
tom 1	(a) Name of Issuer	1	
ши 1.	Dynavax Technologies Corporation	n	
tem 1.	(b) Address of Issuer's Principal Ex		
	2100 Powell Street, Suite 720		
	Emeryville, CA 94608		
tem 2.	(a) Names of Persons Filing:		
	(i) Deep Track Capital, LP (ii) Deep Track Biotechnology Ma: (iii) David Kroin	ster Fund, Ltd.	
tem 2.	(b) Address of Principal Business C	Office:	
		Greenwich, CT 06830 , 190 Elgin Ave, George Town, KY1-9001, Cayman Islands 00 Greenwich Ave, 3rd Floor, Greenwich, CT 06830	
tem 2.	(c) Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States		
tem 2.	(d) Title of Class of Securities		
	Common Stock, \$0.001 par value (the "Common Stock")	
tem 2.	(e) CUSIP No.:		
	268158201		
CUSII	P No. 268158201	SCHEDULE 13G	Page 6 of 9 Pages
tem 3. 1	If this statement is filed pursuant to	o §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the	person filing is a:
(a)	\square Broker or dealer registered under	section 15 of the Act (15 U.S.C. 780);	
(b)	\square Bank as defined in section 3(a)(6)) of the Act (15 U.S.C. 78c);	
(c)	\square Insurance company as defined in	section 3(a)(19) of the Act (15 U.S.C. 78c);	
(d)	☐ Investment company registered u	nder section 8 of the Investment Company Act of 1940 (15 $\mathrm U$.S.C. 80a-8);
(e)	o An investment adviser in accorda	nce with §240.13d-1(b)(1)(ii)(E);	
(f)	\square An employee benefit plan or endo	owment fund in accordance with §240.13d-1(b)(1)(ii)(F);	
(g)	\square A parent holding company or con	trol person in accordance with §240.13d-1(b)(1)(ii)(G);	
(h)	\square A savings associations as defined	in Section 3(b) of the Federal Deposit Insurance Act (12 U.S $$	s.C. 1813);
(i)	☐ A church plan that is excluded fro (15 U.S.C. 80a-3);	om the definition of an investment company under section 3(c	c)(14) of the Investment Company Act of 1940
(j)	☐ A non-U.S. institution in accordan	nce with §240.13d-1(b)(1)(ii)(J);	
(k)	☐ A group, in accordance with §240 specify the type of institution:	0.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance.	rdance with §240.13d-1(b)(1)(ii)(J), please
		_	
CHICK	No 2001E0201	SCHEDIII E 13C	р д . (о.р.
CUSII	P No. 268158201	SCHEDULE 13G	Page 7 of 9 Pages

Item 4. Ownership

The amount beneficially owned by each Reporting Person is determined based on 128,489,060 Common Stock outstanding.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not Applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.

Item 8. Identification and Classification of Members of the Group

Not Applicable.

Item 9. Notice of Dissolution of Group

Not Applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 19, 2023

Deep Track Capital, LP

By: /s/ David Kroin

David Kroin, Managing Member of the General Partner of the

Investment Adviser

Deep Track Biotechnology Master Fund, Ltd.

By: /s/ David Kroin

David Kroin, Director

David Kroin

By: /s/ David Kroin

David Kroin

Exhibit I

JOINT FILING STATEMENT

PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Dated: May 19, 2023

Deep Track Capital, LP

By: /s/ David Kroin

David Kroin, Managing Member of the General Partner of the Investment Adviser

Deep Track Biotechnology Master Fund, Ltd.

By: /s/ David Kroin

David Kroin, Director

David Kroin

By: /s/ David Kroin

David Kroin